Introduction {#s1}
============

Infection of human B-lymphocytes by Epstein-Barr virus results in the establishment of a latent state in which a highly restricted set of viral genes are expressed [@pone.0025922-Rowe1]. This is accompanied by extensive methylation of CpG motifs in non-expressed viral genes [@pone.0025922-Minarovits1], [@pone.0025922-Kalla1], [@pone.0025922-Fernandez1]. In response to physiological stimuli, such as engagement of the B-cell receptor, epigenetic silencing of the viral genome is overturned, resulting in widespread activation of viral gene expression and lytic replication [@pone.0025922-Fernandez1], [@pone.0025922-Miller1]. The expression of a subset of host genes is also altered during this period [@pone.0025922-Yuan1], [@pone.0025922-Broderick1], [@pone.0025922-Chang1], [@pone.0025922-Jones1], [@pone.0025922-Li1], [@pone.0025922-Morrison1], [@pone.0025922-Tsai1], [@pone.0025922-Hsu1], [@pone.0025922-Mahot1].

The switch between latency and the lytic cycle is orchestrated by the viral gene *BZLF1*, which encodes the protein Zta (also known as ZEBRA, BZLF1, EB1, or Z) [@pone.0025922-Countryman1], [@pone.0025922-Sinclair1], [@pone.0025922-Sinclair2]. Zta resembles the AP1 family of bZIP transcription factors but has a unique dimerisation domain and does not form heterodimers with cellular bZIP proteins [@pone.0025922-Petosa1]. Three classes of Zta DNA binding sites (Zta response elements (ZREs)) have been defined for Zta [@pone.0025922-Karlsson1]. Class I ZREs include classical AP1-like recognition elements. However, some Zta binding sites contain a CpG motif and Zta has the unusual property of binding preferentially to these ZREs when they are methylated [@pone.0025922-Bhende1], [@pone.0025922-Bhende2], defining class II ZREs [@pone.0025922-Karlsson1]. Remarkably, some CpG-containing ZREs are only recognized in their methylated form (class III ZREs) [@pone.0025922-Karlsson1], [@pone.0025922-Bhende1], [@pone.0025922-Bhende2], [@pone.0025922-Dickerson1], [@pone.0025922-Heather1], [@pone.0025922-Karlsson2], [@pone.0025922-Bergbauer1]. Methylation of the viral genome occurs during latency and has recently been shown to be required for EBV replication [@pone.0025922-Kalla1]. The ability of Zta to bind to methylated ZREs suggests that Zta may have a direct role in overriding the epigenetic silencing of the viral genome to activate expression of viral genes required for lytic replication.

The requirement for methylation at critical ZREs may also contribute to the establishment of latency during the immortalization of infected cells. The EBV genome is not methylated when it enters cells but the genome gradually becomes methylated during immortalization and the establishment of viral latency [@pone.0025922-Kalla1], [@pone.0025922-Fernandez1]. Zta is transiently expressed during the early period immediately after infection and is required for efficient immortalization [@pone.0025922-Kalla1]. It is therefore essential that Zta should not activate the full lytic replication cycle at this stage. A plausible hypothesis to explain this is that expression of key lytic cycle genes are controlled by class III ZREs that do not function in their unmethylated form.

We developed a computational approach to identify candidate ZREs and applied it to a genome-wide analysis of the EBV genome that revealed many novel target loci. The implications of these data for the ability of EBV to evade epigenetic silencing of the host viral genome is discussed.

Results {#s2}
=======

Prediction of ZREs core sequences bound by Zta using PROMO {#s2a}
----------------------------------------------------------

In order to predict novel ZRE core sequences, we started by searching three well-characterized Zta-responsive promoters from the EBV genome (*BZLF1* promoter (Zp) [@pone.0025922-Flemington1], [@pone.0025922-Lieberman1], [@pone.0025922-Urier1], [@pone.0025922-Packham1], *BRLF1* promoter (Rp) [@pone.0025922-Lieberman1], [@pone.0025922-Packham1], [@pone.0025922-Sinclair3] and *BMRF1* promoter [@pone.0025922-Taylor1] using the PROMO algorithm [@pone.0025922-Fu1], [@pone.0025922-Farrell1] and the position frequency matrix (PFM) for Tranfac 8.3 Zta transcription factor entry T00923 [@pone.0025922-Wingender1], [@pone.0025922-Fu1]. These 3 promoters are known to contain eight previously verified sites: in Zp (ZREIIIA and ZREIIIB); in Rp (ZRE1, ZRE2 and ZRE3) and in BMRF1 promoter (AP1, ZRE(−44) and ZRE (−107)) ([Figure 1](#pone-0025922-g001){ref-type="fig"} and [Table S1](#pone.0025922.s001){ref-type="supplementary-material"}) however, the PROMO algorithm only predicted one of these sites (RpZRE1) using the PFM T00923. In addition, 6 novel sites where predicted ([Table S2](#pone.0025922.s002){ref-type="supplementary-material"}).The ability of Zta to interact with each predicted site was assessed using electrophoretic mobility shift assays (EMSA) ([Figure 1](#pone-0025922-g001){ref-type="fig"}, [Table S2](#pone.0025922.s002){ref-type="supplementary-material"}), although three novel sites were identified, eight known sites were missed and three false positives were predicted indicating that the PFM used had a low sensitivity.

![Evaluation of predicted ZREs in three EBV promoters.\
A. Summary of the known (filled box) and predicted (open box) core ZRE sequences within the proximal 500 nucleotides of the indicated *BZLF1*, *BRLF1 and BMRF1* promoters. The arrows represent the transcription start sites. Stars represent CpG ZREs. B. Double strand oligonucleotides were generated with the core ZRE sequence and at least 10 nucleotides of cognate sequence on either side. Following radio labeling, these were incubated with *in vitro* translated Zta and subject to EMSA. The reactions contained no protein, 0, control lysate, C or Zta, Z. The DNA probes are indicated above with their originating promoters. C. Double strand oligonucleotides were generated with the core ZRE sequence and 10 nucleotides of cognate sequence on either side. Following radio labeling, these were subject to *in vitro* methylation with SssI methyl transferase (+), or a mock reaction (−). Subsequently, they were incubated with *in vitro* translated Zta and subject to EMSA. The reactions contained control lysate, C; or Zta, Z.](pone.0025922.g001){#pone-0025922-g001}

Application of a novel ZRE PFM to predict CpG containing ZREs {#s2b}
-------------------------------------------------------------

A new PFM was generated using the core sequences of five CpG-containing ZREs (denoted PFM~CpG5~) from the promoters described above and the *BRRF1* promoter [@pone.0025922-Dickerson1] ([Figure 2](#pone-0025922-g002){ref-type="fig"}). The accuracy of the PFM was evaluated by searching for ZREs in the well-characterized viral promoters (Rp, Zp and *BMRF1*p). PFM~CpG5~ identified all 5 verified CpG containing sites and predicted two novel sites; one located in Rp, centered on −114, and one located in the *BMRF1* promoter, centered on −148. DNA binding experiments demonstrate that Zta interacts with both sites in a methylation-dependent manner, characteristic of class III ZREs ([Figure 3](#pone-0025922-g003){ref-type="fig"}), thus the new PFM (ZRECpG~5~) has a high level of sensitivity. The PFM~CpG5~ was then used to predict core ZREs in the complete EBV genome. Within the EBV genome a total of 16 novel sequence variants of CpG ZREs were predicted (A--P) ([Figure 3](#pone-0025922-g003){ref-type="fig"}). EMSAs were undertaken with each of the novel ZRE core sequences (both non-methylated and methylated) to evaluate Zta binding ([Figure 3](#pone-0025922-g003){ref-type="fig"}). All but two of the predicted ZRE sequences bound in the methylated form. Only one sequence bound significantly in the unmethylated form. Therefore 13 out of 16 predictions are classified as Class III ZREs, 1 is classified as Class II and 2 did not interact with Zta significantly. Combined with previously published ZREs, this resulted in a total set of 32 distinct sequence variants of ZREs (ZRE~32~) ([Table 1](#pone-0025922-t001){ref-type="table"}).

![Position Frequency Matrix (PFM) of CpG containing ZREs (PFM~CpG5~).\
A. The core seven nucleotide element of the CpG containing ZREs found within the *BRLF1*, *BRRF1*, *and BMRF1* (Rp, Nap and BMRF1p) promoters are shown. B. The number of incidences of each nucleotide at each position and the thus the frequency were calculated. C. The consensus sequence is represented as a sequence LOGO.](pone.0025922.g002){#pone-0025922-g002}

![Zta recognition and methylation dependence of PFM~CpG5~ predicted CpG containing ZREs.\
A. Flow diagram illustrating the information flow from the PFM to the predictions of novel ZREs in the EBV genome and their subsequent evaluation. B. Core heptamer sequences, in both forward and reverse complement, of PFM~CpG5~ predicted CpG containing ZREs within the EBV genome. C. PFM~CpG5~ was used to predict the potential for further ZREs in the EBV genome. Double strand oligonucleotides were generated. Following radio labeling, these were subject to *in vitro* methylation with SssI methyl transferase (+), or a mock reaction (−). Subsequently, they were incubated with *in vitro* translated Zta and subject to EMSA. The reactions contained control lysate, C; or Zta, Z.](pone.0025922.g003){#pone-0025922-g003}

10.1371/journal.pone.0025922.t001

###### List of core ZREs included within ZRE~32~.

![](pone.0025922.t001){#pone-0025922-t001-1}

  ZRE Core Sequence       Class      Names  
  ------------------- ------------- ------- -------------------
  TGAGCCA                TGGCTCA       I        Zp ZREIIIA
  TGAGCCA                TGGCTCA       I          Rp ZRE1
  TGAGCCA                TGGCTCA       I         Zp (−365)
  TTAGCAA                TTGCTAA       I        Zp ZREIIIB
  TGTGTAA                TTACACA       I         DSL ZRE1
  TGAGCAA                TTGCTCA       I         DSL ZRE2
  TGAGCAA                TTGCTCA       I         DSL ZRE7
  TGAGCAA                TTGCTCA       I       BMRF1ZRE(−44)
  TGAGCAA                TTGCTCA       I      BMRF1ZRE(−107)
  TGTGTCA                TGACACA       I         DSL ZRE3
  TGTGTCA                TGACACA       I         DSL ZRE4
  TGTGTCA                TGACACA       I         DSL ZRE6
  TGTGTCA                TGACACA       I       *DHRS9 ZRE1*
  TGTGCAA                TTGCACA       I         DSL ZRE5
  TGTGCAA                TTGCACA       I       *CIITA (221)*
  TGAGTCA                TGACTCA       I        BSLF2+BMLF1
  TGAGTCA                TGACTCA       I        BMRF1 AP-1
  TGAGTCA                TGACTCA       I         *IL8 AP1*
  TGAGTCA                TGACTCA       I      *DHRS9 (ZRE2)*
  TGACTAA                TTAGTCA       I     Fp AP-1-Like Site
  TGTGTCT                AGACACA       I         Zp (−96)
  TGGCACA                TGTGCCA       I       BMRF1 (−173)
  TGAGTAA                TTACTCA       I          *CIITA*
  TGAGTAA                TTACTCA       I          *IL13*
  GTTGCAA                TTGCAAC       I        *IL-8 ZRE*
  GGAG**CG**A          T**CG**CTCC    III          Egr1
  TGAG**CG**A          T**CG**CTCA    II          Rp ZRE2
  TT**CGCG**A          T**CGCG**AA    III         Rp ZRE3
  TGTG**CG**A          T**CG**CACA    III      BMRF1 (−248)
  TGAG**CG**T          A**CG**CTCA    III        Nap ZRE2
  CGGG**CG**A          T**CG**CCCG    III        Nap ZRE1
  CGAGCGA                TCGCTCG      III         CpG5 A
  TGAGCGC                GCGCTCA      II          CpG5 B
  TTGGCGA                TCGCCAA      III         CpG5 C
  TTAGCGA                TCGCTAA      III         CpG5 D
  TGTGCGT                ACGCACA      III         CpG5 E
  TTTGCGA                TCGCAAA      III         CpG5 F
  TCAGCGA                TCGCTGA      III         CpG5 G
  CGTGCGA                TCGCACG      III         CpG5 I
  TGCGCGA                TCGCGCA      III         CpG5 J
  CGCGCGA                TCGCGCG      III         CpG5 K
  AGAGCGA                TCGCTCT      III         CpG5 L
  TGGGCGA                TCGCCCA      III         CpG5 M
  TAAG**CG**A          T**CG**CTTA    III         CpG5 O
  TGAG**CG**G          C**CG**CTCA    III         CpG5 P

Identification of ZRE core binding sequences in the EBV genome {#s2c}
--------------------------------------------------------------

Global analysis of the EBV genome was then undertaken using an exact pattern match with the 32 validated variants of the ZRE core sequence ([Figure 4](#pone-0025922-g004){ref-type="fig"}). This revealed 469 locations within the EBV genome that matched one of the ZRE core sequences ([Table S3](#pone.0025922.s003){ref-type="supplementary-material"} and <http://bioinf.biochem.sussex.ac.uk/EBV>).

![Information flow for the identification of ZREs in the EBV genome.\
Flow diagram illustrating the use of the pattern matching tool (ZRE~32~) to identify exact sequence matches for the 32 verified ZREs in the EBV genome.](pone.0025922.g004){#pone-0025922-g004}

The occurrence of ZREs throughout the EBV genome appears to be widespread; with 81 out of 86 (94%) EBV promoters containing at least 1 ZRE core sequence ([Table S4](#pone.0025922.s004){ref-type="supplementary-material"}). This suggests that Zta has the potential to regulate the expression of the majority of EBV genes. Furthermore, 58 EBV promoters contained at least 1 CpG containing ZRE. These regions are methylated during latency [@pone.0025922-Kalla1], [@pone.0025922-Fernandez1], suggesting that methylation-dependent Zta interaction with ZREs could influence the expression of a broad range of EBV genes once Zta is synthesized at the onset of lytic cycle.

Of particular relevance to the control of EBV gene expression immediately after infection are 22 EBV genes that contained CpG ZREs but have no methylation independent ZREs in their promoters ([Table 2](#pone-0025922-t002){ref-type="table"}). These genes are prime contenders to be regulated in a strictly methylation-dependent manner by Zta. These were originally classified as displaying early lytic, late lytic and latent patterns of gene expression [@pone.0025922-Farrell1], but importantly, genome wide expression studies revealed that all are up regulated during lytic cycle in BL cells, with the majority reaching peak levels approximately 24 hours after lytic activation [@pone.0025922-Yuan1].

10.1371/journal.pone.0025922.t002

###### EBV genes that contain CpG ZREs but have no methylation independent ZREs in their regulatory regions, with the kinetics and extent of any change in their expression in Akata cells undergoing lytic cycle [@pone.0025922-Yuan1].

![](pone.0025922.t002){#pone-0025922-t002-2}

  Cycle          Promoter/Gene   Class   Sequence   Offset FromGene Start   Peakexpressiontime (hr)   fold changeexpression
  ------------- --------------- ------- ---------- ----------------------- ------------------------- -----------------------
  early lytic        BALF1        II     TCGCTCA             −74                      12                       8.2
                                  II     TCGCTCA            −138                                     
                                  III    TCGCCCA            −383                                     
                                  III    ACGCTCA            −416                                     
  late lytic         BALF4        III    TCGCGCA            −164                      24                      15.2
                                  III    TCGCTCG            −254                                     
                                  III    ACGCACA            −414                                     
  unknown            BARF0        III    CGAGCGA             45                       36                       7.3
                                  III    TGCGCGA             −45                                     
  early lytic       BARF1.2       II     TGAGCGA             114                      24                       9.2
                                  II     TGAGCGA             50                                      
                                  III    TGGGCGA            −488                                     
  early lytic     BBLF2/BBLF3     III    TCGCCCA             91                       12                      19.5
  early lytic        BBLF4        III    TCGCTCG            −221                      12                       7.9
                                  III    TCGCACA            −235                                     
                                  III    ACGCTCA            −357                                     
  late lytic         BBRF1        III    AGAGCGA             −31                      24                        7
                                  III    TTCGCGA            −414                                     
  late lytic         BBRF3        III    TGGGCGA             −34                      24                      20.5
                                  III    TTTGCGA            −177                                     
  late lytic         BDLF1        III    TCGCCCG            −390                      24                      21.5
  late lytic         BGLF2        II     TCGCTCA             133                      24                      14.3
  early lytic        BGLF4        II     GCGCTCA            −260                       8                      12.1
                                  III    TCGCTTA            −316                                     
  late lytic      BGRF1/BDRF1     III    CGGGCGA             −49                      24                       8.3
  late lytic         BKRF2        II     TGAGCGC             155                      24                      14.1
                                  III    TTAGCGA             185                                     
  early lytic        BKRF4        III    TTAGCGA             −70                      24                      16.3
                                  III    TGAGCGG            −246                                     
                                  III    CGTGCGA            −302                                     
  early lytic        BLLF2        III    CCGCTCA             −18                      24                      12.4
                     BOLF1        III    TCGCCCG             175                      24                       4.2
                                  III    TCGCTGA             −65                                     
  late lytic         BORF1        III    CGGGCGA             130                      24                      12.4
                                  III    TGCGCGA             10                                      
                                  III    TGAGCGG             −20                                     
  early lytic        BRRF1        III    CGGGCGA             −25                      24                        7
                                  III    TGAGCGT             −53                                     
  late lytic         BTRF1        III    TGGGCGA            −292                      24                       8.5
  unknown        BWRF1 repeats    III    CGGGCGA             72                        ∼                        ∼
                                  III    CGGGCGA             46                                      
                                  III    GGAGCGA            −422                                     
  latent           Cp EBNAs       III    TGGGCGA             −70                    24--48                   6--8.2
                                  III    TTTGCGA            −204                                     
                                  III    GGAGCGA            −248                                     
  latent           Wp EBNAs       III    TCAGCGA             180                      48                       6.1

Three of these promoters were chosen to question whether Zta interacts with the novel CpG ZREs *in vivo*; *BKRF4*, *BGLF4* and *BTRF1*. The location of the CpG ZREs in each promoter is indicated in [Figure 5](#pone-0025922-g005){ref-type="fig"}. Lytic cycle was activated in Akata cells [@pone.0025922-Takada1] by surface immunoglobulin ligation, undertaken in the presence of acyclovir to inhibit genome replication. Chromatin was subjected to Zta immunoprecipitation (ChIP) and the interaction of Zta with these promoters was assessed by Q-PCR. The ability of this antibody to precipitate Zta bound to chromatin is demonstrated by western blotting in [Figure 6](#pone-0025922-g006){ref-type="fig"}. In addition, we show that Zta as opposed to a control antibody specifically precipitates chromatin from a region of oriLyt containing multiple ZREs. Using primer sets proximal to the CpG ZREs from *BKRF4*, *BGLF4* and *BTRF1* compared to primer sets from three regions of the EBV genome devoid of ZREs, we reveal that Zta specifically binds to all three of these promoters that contain novel CpG ZREs *in vivo* ([Figure 7](#pone-0025922-g007){ref-type="fig"}).

![ZREs in the EBV genome.\
The entire EBV genome was subjected to an exact pattern match search, using the ZRE~32~ set of core sequences. Each site was classed by binding behaviour, and plotted by the first nucleotide of the site to form a genome wide map of ZREs. Class I sites are indicated by blue diamonds, Class II sites are indicated by red stars, Class III sites are indicated by green triangles, and gene starts and direction are indicated by arrows. The location of transcription start sites and their orientation are indicated by arrows.](pone.0025922.g005){#pone-0025922-g005}

![Chromatin precipitation (ChIP) analysis of Zta.\
Akata cells were induced or not to enter lytic cycle by the addition if anti-IgG as indicated. 48 hours later the cross-linking agent was added and chromatin and total proteins were harvested. A. The proteins were subject to western blot analysis for Zta expression. B. A chromatin precipitation experiment was undertaken with the Zta antibody and a control antibody. The precipitated chromatin and input chromatin were subject to western blot analysis to detect Zta protein. C. The location of ZREs and Q-PCR amplicons are illustrated for a region central to OriLyt left and for a region flanking OriLyt left. The genome co-ordinates are indicated. Transcription start sites and the direction of transcription are shown by arrows. Blue diamonds represents the class I ZREs. The amplicons used for Q-PCR are indicated as black horizontal bars. D. Association of Zta with OriLyt left was assessed using chromatin precipitation from Akata cells in lytic cycle, followed by Q-PCR. The binding is shown relative to maximal binding to Orilyt left.](pone.0025922.g006){#pone-0025922-g006}

![Chromatin precipitation (ChIP) analysis of Zta binding with the EBV genome.\
A. Five regions of the EBV genome are illustrated, together with gene names and sequence co-ordinates. Three contain core CpG ZREs and two do not. Transcription start sites and the direction of transcription are indicated with arrows. Green triangles represent class III CpG ZREs and the red star represents a class II ZRE. The amplicons used for Q-PCR are indicated as black horizontal bars. F. Association of Zta with the indicated regions of the EBV genome was assessed using chromatin precipitation from Akata cells in early lytic cycle (stalled prior to DNA replication with acyclovir), followed by Q-PCR. The binding is shown relative to maximal binding to OriLyt left (OL5).](pone.0025922.g007){#pone-0025922-g007}

Discussion {#s3}
==========

Following several iterations of a predictive and evaluative approach, we identified a set of 32 distinct sequence variants in the core 7-nucleotide sequence to which Zta can bind. This includes 20 variants containing a CpG motif, the majority of which (90%) are only recognized by Zta when they are methylated.

The consensus binding sites identified for non-CpG ZREs are similar to the binding sites originally described for Zta ([Figure 8](#pone-0025922-g008){ref-type="fig"}). In contrast, the binding sites for CpG containing ZREs are remarkably different. This sequence is dominated by an almost invariant G 5′ to the absolute prerequisite for me-CpG at positions 1′ and 2′ in the right-half of the core sequence.

![Sequence Logos CpG and non-CpG ZREs.\
The sequences comprising ZRE~32~, were divided into those sites which do not contain a CpG motif, class I ZREs and those that do, class II and class III ZREs. A. A PFM was created from (PFM~non-CpG\ ZREs~) and is displayed using relative letter height. B. A PFM was created from (PFM~CpG\ ZREs~) and is displayed using relative letter height.](pone.0025922.g008){#pone-0025922-g008}

The identification of 58 EBV promoters that harbor methylation dependent CpG ZREs, combined with the knowledge that the EBV genome is heavily methylated during latency [@pone.0025922-Kalla1], [@pone.0025922-Fernandez1], suggests that Zta plays an important role in overturning epigenetic silencing of over half of the EBV genes during lytic replication. Indeed, all three of the promoters tested displayed a strong interaction with Zta *in vivo* in ChIP analyses. A genome-wide DNA binding analysis was recently published identifying sequences to which a mutant form of Zta, that is replication and transactivation dead, can interact [@pone.0025922-Kalla1]. This report highlighted the strength of the interaction between Zta and methylation dependent binding of Zta to CpG ZREs in the EBV genome.

The EBV genes that contain only methylation-dependent ZREs are of particular interest. All of these genes are heavily methylated during viral latency yet unmethylated following replication and immediately after infection [@pone.0025922-Kalla1], [@pone.0025922-Fernandez1]. Several are required for EBV replication and include components of the helicase/primase complex (*BBLF4*, *BBLF2/BBLF3*), the viral protein kinase (*BGLF4*), and glycoproteins gL (*BKRF2*) and gB (*BALF4*). In addition, the promoters for *BBLF4* and *BBLF2/BBLF3* have been validated as being targets for Zta that are completely dependent on methylation for Zta activation [@pone.0025922-Kalla1]. Our discovery that one in five EBV promoters contain CpG ZREs but have no methylation independent ZREs strongly supports the hypothesis that the unmethylated status of the EBV genome guards against the expression of the full range of lytic genes and therefore lytic replication during the establishment of latency.

Zta is the prototypic member of a family of transcription factors that interact with DNA in a methylation-dependent manner. C/EBP alpha has recently been shown to share the same characteristics [@pone.0025922-Rishi1]. It has been suggested that the interaction between C/EBP alpha and methylated sequence elements are needed to activate tissue specific genes during differentiation [@pone.0025922-Rishi1].

The biphasic methylation cycle is observed for several different classes of viruses that establish latency [@pone.0025922-Fernandez1]. Yet even KSHV, which is closely related to EBV, does not contain a functional Zta homologue. The question arises as to how the methylated genomes of these viruses can be reactivated. We suggest that the recent discovery that a cellular transcription factor also has methylation dependent DNA binding properties [@pone.0025922-Rishi1] implies that other viruses may rely on host methylation dependent transcription factors to differentially control the expression of their genomes during the establishment of latency or replication.

Methods {#s4}
=======

Computational prediction of ZREs core sequences bound by Zta {#s4a}
------------------------------------------------------------

The starting point for the computational approach was the Zta transcription factor entry T00923 in Transfac 8.3 that includes 6 experimentally verified ZRE binding sites [@pone.0025922-Wingender1], [@pone.0025922-Fu1]. The Promo algorithm [@pone.0025922-Farre1], [@pone.0025922-Messeguer1] generated a position weight matrix (PWM) based on the T00923 transcription factor entry, and we used it to search 3 well-characterized Zta-responsive promoters from the EBV genome (*BZLF1* promoter (Zp) 500 bp upstream of the published transcription start sites were included. A positive match was taken as one with an 85% similarity rate.

DNA binding assays {#s4b}
------------------

Electrophoretic mobility shift assays (EMSA) were undertaken using Zta protein generated in a wheat germ *in vitro* translation system (Promega) and \[^32^P\]-radio labeled double strand oligonucleotides, as described previously [@pone.0025922-Flower1].

Where indicated in the figure, the central CpG motif was methylated on both cytosine residues during synthesis (Sigma) or methylated probes were synthesized or methylated *in vitro* using the CpG methyltransferase M.sssI (NEB) [@pone.0025922-Heather1].

Zta protein (B95-8 strain) was *in vitro* translated using wheatgerm extract (Promega).

1.  Zp (−96): TAAATTTAGGTGTGTCTATGAGGTACA

2.  Zp (−365): ACAGATGGACCTGAGCCACCCGCC

3.  Zp (−662): CCTCTTTGGCTGACACACCTCTCGCCC

4.  Rp (−204) & RpZRE2: CATCTTGTCCTGTGATAAAATCGCTCATAAGCTTAGT

5.  Rp (−439 & −447): ATGACTCGGGTGTGTCCTTGTGTGAGGTCTCACCTG

6.  Rp (−114): CACTCATACTTAAGCGATGCTGATGCA

7.  *BMRF1*p (−173): TGGGGGGTGGTGTGCCATACAAGGGAGC

8.  *BMRF1*p (−248): CCTTGGTGGATGTGCGAGCCATAAAGCA

9.  CpG5 A: AAGCGATGGCCGAGCGATGACTCGTGT

10. CpG5 B: TCCAGATGACTGAGCGCACGGCCTCAA

11. CpG5 C: AAAGATCTGGTTGGCGATCCGGTACAC

12. CpG5 D: TTGGAAAACATTAGCGACATTTACCTG

13. CpG5 E: TTTGGCGTCATGTGCGTCTGGATGACA

14. CpG5 F: CAGACTCTGGTTTGCGAGGCTGGGCGG

15. CpG5 G: GCCGCCGCACTCAGCGAGGAGGCCTGC

16. CpG5 H: CGAGGAGGCCTGCGCGTGTTCCTCAAC

17. CpG5 I: CCAATGTCTGCGTGCGAGCCGGGCTTG

18. CpG5 J: CTTTGCGCTCTGCGCGAGGACGAGCTC

19. CpG5 K: GCAGGGCCCCCGCGCGATCTAGGTAGG

20. CpG5 L: CTCATAGGTCAGAGCGACATAGAGGCG

21. CpG5 M: TTTCAAGTCGTGGGCGAATTAACTGAG

22. CpG5 N: AGCAAGGTGCTGGGCGTGGACCGCGCG

23. CpG5 O: CACTCATACTTAAGCGATGCTGATGCA

24. CpG5 P: GTCATGTAGGTGAGCGGGCAGTCCTTG

Chromatin Immunoprecipitation {#s4c}
-----------------------------

Chromatin was prepared from Akata cells [@pone.0025922-Takada1], following induction with anti IgG, in the presence of 100 µM acyclovir essentially as described in [@pone.0025922-BarkJones1], except that a mixture of Protein A and protein G were used to capture antibodies. Precipitation was undertaken using an amino-terminal Zta antibody from Santa Cruz.

Primers: absolute genomic position and sequence

1.  OL5 F 41195-41216 CAGCTGACCGATGCTCGCCA

2.  OL5 R 41342-41323 ATGGTGAGGCAGGCAAGGCG

3.  BKRF4 F 98591-98611 CATTGCTCTCTGAGCGGTTA

4.  BKRF4 R 98688-98667 ACCAGATGCTTCTTGGAGTTG

5.  BGLF4 F 111611-111631 ACCGAGGCTCTTAGTTGCTG

6.  BGLF4 R 111686-111666 GTTGCGGACATGGTGACTTA

7.  BTRF1 F 126981-127000 AGCTACGCAATCGGAGTCA

8.  BTRF1 R 127052-127034 GGAGGCGCAGTCTAGCAG

Region with no ZREs

1.  OR1 F 139875-139895 CCGCATGTCCAACCACCACG

2.  OR1 R 139997-139976 ATGCTACCTAGGCCTGCGTCC

3.  OL1 F 38229-38249 GCGCAACAGTGCCACCAACC

4.  OL1 R 38302-38282 CAGGACCTGGCGGTAGTGCAG

5.  MID-BORF1 F 60768-60788 TGCCTGAGACCTCTCGGACGG

6.  MID-BORF1 R 60817-60792 CCACGACGCAGTCCTTAGGATCATG

Generation and application of ZRE PFMs {#s4d}
--------------------------------------

A position frequency matrix (PFM~CpG5~) was created using 5 CpG containing ZRE core binding sequences ([Figure 3](#pone-0025922-g003){ref-type="fig"}) and used to search (a) the 3 EBV promoters using the algorithm Matscan [@pone.0025922-Blanco1], and (b) the complete Human herpesvirus 4 (Epstein-Barr virus) Genome NC_007605 extracted from GenBank [@pone.0025922-Benson1]. An 85% similarity score was used to define a positive match to the PFM~CpG5~. PFMs for non-CpG ZREs and CpG ZREs were generated in a similar manner and displayed using WEBLOGO [@pone.0025922-Schneider1].

Exact pattern matching was employed to search for each of the 32 core ZRE sequences within the EBV genome. A rolling window of seven nucleotides was used and an exact comparison of each of the core ZREs sequences, was made. In addition, the reverse complement of the sequence was checked in the same manner.

A MySQL database of the locations of the exact matches within the EBV genome was generated and simple analyses can be conducted using a web interface which is publically available at URL: <http://bioinf.biochem.sussex.ac.uk/EBV/>. The database uses gene annotations extracted from the RefSeq NC_007605 entry and data from the exact match predictions.

Supporting Information {#s5}
======================

###### 

The sequences of published ZREs used in this study are shown, together with their names and references. CpG motifs are shown in bold.

(DOCX)

###### 

Click here for additional data file.

###### 

ZREs predicted using PROMO, together with the results of their evaluation by DNA binding assays (EMSA) are shown. CpG motifs are shown in bold.

(DOCX)

###### 

Click here for additional data file.

###### 

All ZREs in the EBV genome are shown with the position of the central nucleotide using RefSeq NC_007605.

(DOCX)

###### 

Click here for additional data file.

###### 

The number of ZREs close to each EBV promoter (between −1000 and +200 from the annotated gene start) are shown using RefSeq NC_007605.

(DOCX)

###### 

Click here for additional data file.
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